GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (STU:9IB) » Definitions » 5-Year Yield-on-Cost %

Infant Bacterial Therapeutics AB (STU:9IB) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 28, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Infant Bacterial Therapeutics AB 5-Year Yield-on-Cost %?

Infant Bacterial Therapeutics AB's yield on cost for the quarter that ended in Dec. 2024 was 0.00.


The historical rank and industry rank for Infant Bacterial Therapeutics AB's 5-Year Yield-on-Cost % or its related term are showing as below:



STU:9IB's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.715
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Infant Bacterial Therapeutics AB's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's 5-Year Yield-on-Cost % falls into.


;
;

Infant Bacterial Therapeutics AB 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Infant Bacterial Therapeutics AB is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Infant Bacterial Therapeutics AB  (STU:9IB) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Infant Bacterial Therapeutics AB 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines